To the full analysis
Strata Critical Medical stock: growth
SRTAStrata Critical Medical reported $197.14M in revenue for fiscal 2025, down 20.7% on the prior year, up 60.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
44.6%
per year from 2019 to 2025, per share −10.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2019 | |
|---|---|
| Revenue | 44.6% |
| Revenue per share | −10.8% |
| Earnings | no data |
| Earnings per share | no data |
| Free cash flow | no data |
| Free cash flow per share | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $31.2M | −$10.84M | −$11.16M |
| 2021 | $50.53M | −$40.05M | −$15.91M |
| 2022 | $146.12M | −$27.26M | −$37.86M |
| 2023 | $225.18M | −$56.08M | −$34.46M |
| 2024 | $248.69M | −$27.31M | −$35.51M |
| 2025 | $197.14M | $41.35M | −$59.92M |
Revenue by segment
How Strata Critical Medical, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Logistics$176.8M90%
- Clinical$20.3M10%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Logistics | $176.79M | 89.7% |
| Clinical | $20.35M | 10.3% |
| Total revenue | $197.14M | 100% |
Revenue by region
Where Strata Critical Medical, Inc. generates its revenue.
- United States88%
- Outside the US12%
Figures as a table
| 2022 | 2023 | 2024 | Share 2024 | |
|---|---|---|---|---|
| United States | $133.3M | $190.74M | $218.75M | 88% |
| Outside the US | $12.82M | $34.44M | $29.95M | 12% |
| Total revenue | $146.12M | $225.18M | $248.69M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.